Issue 153 • April 2025

Are European biopharma manufacturers ‘nearshoring’?

Experts debate whether European manufacturers are preferring domestic operations as the continent competes with Asia and the US

Briefing

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Feature

Metabolism errors elicit therapy development challenges

Feature

GLP-1RAs and opioid use disorder: a new frontier in addiction treatment

Interview

USAID funding fallout: sponsors, and agencies may have to fill funding gap